Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
-
Narrated by:
-
By:
Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.
Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext
adbl_web_anon_alc_button_suppression_t1
No reviews yet